BMJ study confirms hair loss risk with GLP-1 drugs: what Canadian patients should know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A July 2026 BMJ observational study of more than 50,000 people with Type 2 diabetes found that GLP-1 receptor agonists, a drug class that includes semaglutide (sold in Canada as Ozempic for diabetes and Wegovy for weight management, both made by Novo Nordisk) and tirzepatide (sold in Canada as Mounjaro), are associated with a 37% higher relative risk of alopecia compared with SGLT-2 inhibitors and a 68% higher relative risk compared with DPP-4 inhibitors. Absolute rates stayed low: roughly 3 to 9 cases per 1,000 people per year. For the estimated three million Canadian adults currently taking GLP-1 drugs, according to a 2026 Leger survey cited by Global News, this finding adds a documented side-effect profile to a class of medications that many Canadians are using with limited specialist oversight.

The study's authors note that hair loss does not typically cause physical harm but can carry real psychosocial consequences, affecting self-esteem, quality of life, and willingness to stay on treatment. That last point matters in Canada, where access to GLP-1 medications often involves months-long waits for obesity medicine specialists, significant out-of-pocket costs, and inconsistent provincial drug coverage. A patient who stops treatment because of undisclosed hair shedding may face those access barriers all over again.

What this means in Canada

Ozempic and Mounjaro are approved by Health Canada for Type 2 diabetes management. Wegovy received Health Canada approval for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. As of this writing, Health Canada has not issued a specific safety communication or label update addressing the hair loss signal identified in this BMJ study or in the June 2026 Journal of the American Academy of Dermatology study of more than one million participants globally. The US Food and Drug Administration (FDA, the American drug regulator) has stated it is evaluating the potential safety signal, but no formal FDA label change has been announced, and Health Canada's position remains separate from the FDA's.

Provincial drug coverage for GLP-1 medications varies widely. Ontario's OHIP drug benefit (ODB) program covers Ozempic for eligible patients with Type 2 diabetes but does not routinely cover Wegovy for weight management. Quebec's RAMQ covers semaglutide for diabetes indications under specific criteria. British Columbia's PharmaCare and Alberta's AHCIP have similarly narrow coverage tied to diabetes diagnoses. Patients using these drugs off-label or for weight management alone typically pay out of pocket, with monthly costs ranging from roughly CAD $250 to $500 depending on dose and pharmacy.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a position statement specifically on GLP-1-associated hair loss. The Canadian Dermatology Association's Quebec regional director, Dr. Elena Netchiporouk, told Global News that the finding is consistent with what dermatologists already know: rapid weight loss of any cause triggers temporary hair shedding, a condition called telogen effluvium.

What changed

The BMJ study is not the first to flag this association, but it is among the largest and most methodologically direct comparisons to date. Researchers compared GLP-1 users head-to-head against patients on other diabetes drug classes rather than against a general population, which makes the signal harder to dismiss as a background rate. A June 2026 study in the Journal of the American Academy of Dermatology covering more than one million participants globally found a significantly increased hair loss risk with semaglutide and tirzepatide specifically, and noted that rapid weight loss alone may not fully explain the association. An April 2026 Sage Journals study reached a similar conclusion, pointing to pharmacovigilance databases and clinical cohorts as converging sources of evidence.

Taken together, these three studies published within months of each other represent a shift from anecdotal reports to peer-reviewed, multi-cohort evidence. That shift is what makes the BMJ paper newsworthy, even though the absolute risk numbers remain modest.

What Canadian patients should know

Telogen effluvium is the medical term for the type of hair shedding most commonly linked to GLP-1 use. It is a temporary, non-scarring form of hair loss in which a large proportion of hair follicles shift simultaneously into a resting phase, typically triggered by physiological stress such as rapid caloric deficit or significant weight change. Shedding usually begins two to three months after the triggering event and can continue for up to six months. In most cases, hair regrows once the body adapts to a stable weight.

Dr. Netchiporouk told Global News that patients who lose weight more gradually, roughly one pound per week or less, may reduce the severity of shedding. She also noted that gastrointestinal side effects common with GLP-1 drugs, including nausea and reduced food intake, can cause nutritional deficiencies that compound hair loss independently of weight change. Ensuring adequate protein and micronutrient intake while on these medications is worth discussing with a prescribing physician or a registered dietitian.

For Canadians accessing GLP-1 prescriptions through telehealth platforms such as Felix, Maple, or Telus Health, or through in-person obesity medicine clinics, the practical step is to ask the prescribing clinician about dose titration. Dr. Netchiporouk suggested that starting at a lower-than-standard dose, or titrating more slowly, may reduce the abruptness of weight loss and therefore reduce hair shedding. Science & Humans (scienceandhumans.com), a Canadian men's and women's health platform, is among the providers offering GLP-1 prescriptions in Canada, though patients should confirm current formulary and coverage details directly with any provider.

US-based platforms such as Hone Health, Midi, and Winona do not serve Canadian patients and are not a relevant option for people in Canada.

Limitations and open questions

The BMJ study is observational, meaning it cannot establish that GLP-1 drugs directly cause hair loss, only that the association exists after controlling for available confounders. The study population had Type 2 diabetes, so findings may not translate directly to people taking these drugs solely for weight management, a growing segment of Canadian users.

The mechanism is not settled. The BMJ authors point to broad metabolic, hormonal, and immunological effects of GLP-1 receptor agonists as possible contributors beyond weight loss alone. The June 2026 JAAD study similarly concluded that rapid weight loss does not fully account for the signal. Whether the drug itself acts on hair follicle biology directly is an open research question.

Health Canada has not yet issued guidance on this signal, and the SOGC has not published a position statement. The FDA's review is ongoing. Until regulators act, the hair loss risk is not listed as a standard warning on Canadian product monographs for these drugs, which means patients may not be informed of it at the point of prescription.

If you are experiencing significant hair shedding while on a GLP-1 medication, a referral to a dermatologist is reasonable. Hair loss that is patchy, involves the scalp in distinct areas, or does not begin to slow after six months warrants clinical evaluation to rule out other causes.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.